Skip to main content

Advertisement

SpringerLink
Log in

Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use

  • Respiratory Infections (F Arnold, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Starting from 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in several countries. This paper discusses some of the problems recently emerged after PCV13 use and their clinical impact. The impact of PCV13 has been relevant and has saved millions of children and adults by severe infectious diseases. However, it seems likely that in the future, effectiveness of the vaccine might be even higher than that presently evidenced. This is because long-term administration of PCV13 to the pediatric population can favor a more extensive reduction of nasopharyngeal colonization with vaccine serotypes of both vaccinated and unvaccinated subjects and further reduce invasive pneumococcal disease in all the individuals (herd immunity). While waiting for new vaccines to be able to overcome the problem of a limited number of pneumococcal strains included in PCV13, it is recommended to increase pneumococcal vaccination coverage in the entire pediatric population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. U.S. Food and Drug Administration. Prevnar 13. Available at: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm. Available at: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm. Accessed 4 Sept 2017.

  2. European Medicines Agency. Prevenar 13. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/human_med_001220.jsp&mid=WC0b01ac058001d124. Accessed 4 Sept 2017.

  3. Unicef Supply Division. Pneumococcal conjugate vaccine: Supply and Demand Update. Available at: https://www.unicef.org/supply/files/PCV_Update_Note_July_2014.pdf. Accessed 4 Sept 2017.

  4. Centers for Disease Control and Prevention. Pneumococcal vaccine recommendations. Available at: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html. Accessed 4 Sept 2017.

  5. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962–73. https://doi.org/10.1016/S0140-6736(10)62225-8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Esposito S, Principi N. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015;10(10):1599–607. https://doi.org/10.2217/fmb.15.81.

    Article  CAS  PubMed  Google Scholar 

  7. Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–25. https://doi.org/10.1093/cid/ciw067.

    Article  CAS  PubMed  Google Scholar 

  8. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–99. https://doi.org/10.1128/CMR.00024-15.

    Article  PubMed  PubMed Central  Google Scholar 

  9. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371(20):1889–99. https://doi.org/10.1056/NEJMoa1401914.

    Article  Google Scholar 

  10. • Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139–47. An interesting study showing that PCV13 vaccination of immunocompromised adults may substantially reduce the residual burden until herd immunity from pediatric PCV13 is fully established. https://doi.org/10.1093/cid/civ803.

    Article  PubMed  Google Scholar 

  11. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. https://doi.org/10.1016/S1473-3099(15)70044-7.

    Article  PubMed  Google Scholar 

  12. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203–7. https://doi.org/10.1097/INF.0b013e318275614b.

    Article  PubMed  Google Scholar 

  13. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. https://doi.org/10.1371/journal.pmed.1001517.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24. https://doi.org/10.1093/cid/ciu006.

    Article  CAS  PubMed  Google Scholar 

  15. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–73. https://doi.org/10.1093/cid/ciu524.

    Article  CAS  PubMed  Google Scholar 

  16. Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134(2):210–7. https://doi.org/10.1542/peds.2014-0473.

    Article  PubMed  Google Scholar 

  17. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. https://doi.org/10.1016/S1473-3099(14)71081-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–55. https://doi.org/10.1586/erv.12.53.

    Article  CAS  PubMed  Google Scholar 

  19. Del Amo E, Esteva C, Hernandez-Bou S, Galles C, Navarro M, Sauca G, et al. Serotypes and clonal diversity of Streptococcus pneumoniae causing invasive disease in the era of PCV13 in Catalonia, Spain. PLoS One. 2016;11:e0151125.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Inf Secur. 2009;59:75–82.

    Google Scholar 

  21. • Moraga-Llop F, Garcia-Garcia JJ, Díaz-Conradi A, Ciruela P, Martínez-Osorio J, González-Peris S, et al. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage. Pediatr Infect Dis J. 2016;35(4):460–3. A study showing that 9 patients were considered to have a PCV13 vaccine failure and among these patients serotype 3 was isolated in 6, serotype 19A in 2 and serotype 6B in 1. https://doi.org/10.1097/INF.0000000000001041.

    Article  PubMed  Google Scholar 

  22. Olarte L, Barson WJ, Bradley JS, Tan TQ, Lin PL, Romero JR, Givner LB, Hoffman JA, Hultén KG, Mason EO, Kaplan SL Invasive pneumococcal disease in infants aged 0-60 days in the United States in the 13-valent pneumococcal conjugate vaccine era. J Pediatric Infect Dis Soc 2017. https://doi.org/10.1093/jpids/pix034.

  23. Centers for Disease Control and Prevention. 2015 Childhood Pneumococcal Conjugate Vaccine (PCV) Coverage Report. Available at: https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/pcv/reports/2015.html. Accessed 4 Sept 2017.

  24. Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, McCracken GH Jr. The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. J Pediatric Infect Dis Soc. 2017;6(3):253–9. https://doi.org/10.1093/jpids/piw005.

    Article  PubMed  Google Scholar 

  25. •• Esposito S, Colombo C, Tosco A, Montemitro E, Volpi S, Ruggiero L, et al. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. J Cyst Fibros. 2016;15(3):366–71. A study showing the role of Streptococcus pneumoniae in cystic fibrosis. https://doi.org/10.1016/j.jcf.2015.05.008.

    Article  PubMed  Google Scholar 

  26. Principi N, Iughetti L, Cappa M, Maffeis C, Chiarelli F, Bona G, et al. Streptococcus pneumoniae oropharyngeal colonization in school-age children and adolescents with type 1 diabetes mellitus: impact of the heptavalent pneumococcal conjugate vaccine. Hum Vaccin Immunother. 2016;12(2):293–300. https://doi.org/10.1080/21645515.2015.1072666.

    Article  PubMed  Google Scholar 

  27. Esposito S, Terranova L, Patria MF, Marseglia GL, Miraglia del Giudice M, et al. Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine. BMC Infect Dis. 2016;16:12.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine. J Infect Dis. 2005;192(3):367–76. https://doi.org/10.1086/431679.

    Article  CAS  PubMed  Google Scholar 

  29. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. https://doi.org/10.1086/648593.

    Article  PubMed  Google Scholar 

  30. Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15(1):419. https://doi.org/10.1186/s12879-015-1147-x.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine preventable diseases in Australia 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Supp):S1–167.

    PubMed  Google Scholar 

  32. •• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. A study showing that PCV13 appears highly effective against invasive pneumococcal disease among children in the USA in the context of routine and catch-up schedules, although some new vaccine antigens could not be assessed. https://doi.org/10.1016/S2213-2600(16)00052-7.

    Article  CAS  PubMed  Google Scholar 

  33. Camilli R, D'Ambrosio F, Del Grosso M, Pimentel de Araujo F, Caporali MG, Del Manso M, et al. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Vaccine. 2017;35(35):4587–93. https://doi.org/10.1016/j.vaccine.2017.07.010.

    Article  PubMed  Google Scholar 

  34. Fry N, Kapatai G, Sheppard C, Litt D, Collins S, Ladhani S, et al. The fall and rise of serotype 19A in invasive pneumococcal disease: application of whole genome sequencing to investigate the recent rise in England and Wales. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016; Glasgow, UK.

  35. Corcoran M, Vickers I, Fitzgerald M, Mereckiene J, Murchan S, Cotter S, et al. The persistence of serotype 19A—despite the introduction of PCV13 vaccine. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016; Glasgow, UK.

  36. Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34(11):1168–74. https://doi.org/10.1097/INF.0000000000000849.

    Article  PubMed  Google Scholar 

  37. • Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. This study shows the geographic diversity of pneumococcal serotypes and highlights the importance of continued surveillance to guide vaccine design and recommendations. https://doi.org/10.1371/journal.pone.0177113.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208–18. https://doi.org/10.1183/13993003.01451-2015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–66. https://doi.org/10.1016/j.vaccine.2014.11.011.

    Article  CAS  PubMed  Google Scholar 

  40. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–9. https://doi.org/10.1016/j.vaccine.2014.03.065.

    Article  PubMed  Google Scholar 

  41. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits crossfunctional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29(41):7207–11. https://doi.org/10.1016/j.vaccine.2011.06.056.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31(3):297–301. https://doi.org/10.1097/INF.0b013e318247ef84.

    Article  PubMed  Google Scholar 

  43. Diamantino-Miranda J, Aguiar SI, Carriço JA, Melo-Cristino J, Ramirez M. Clonal and serotype dynamics of serogroup 6 isolates causing invasive pneumococcal disease in Portugal: 1999-2012. PLoS One. 2017;12(2):e0170354. https://doi.org/10.1371/journal.pone.0170354.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax. 1998;53(3):159–62. https://doi.org/10.1136/thx.53.3.159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–51. https://doi.org/10.1007/s12325-013-0007-6.

    Article  CAS  PubMed  Google Scholar 

  46. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501–8. https://doi.org/10.1097/INF.0b013e31824de9f6.

    Article  PubMed  Google Scholar 

  47. • Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. PLoS One. 2017;12(8):e0183191. A study showing the good effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months. https://doi.org/10.1371/journal.pone.0183191.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. https://doi.org/10.1016/S1473-3099(14)70822-9.

    Article  CAS  PubMed  Google Scholar 

  49. Slotved HC, Dalby T, Harboe ZB, Valentiner-Branth P, Casadevante VF, Espenhain L, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon. 2016;2(11):e00198. https://doi.org/10.1016/j.heliyon.2016.e00198.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. https://doi.org/10.1542/peds.2009-3027.

    Article  PubMed  Google Scholar 

  51. Kieninger DM, Kueper K, Steul K, Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192–203. https://doi.org/10.1016/j.vaccine.2010.04.008.

    Article  CAS  PubMed  Google Scholar 

  52. Snape MD, Klinger CL, Daniels ED, John TM, Layton H, Rollinson L, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29(12):e80–90. https://doi.org/10.1097/INF.0b013e3181faa6be.

    Article  PubMed  Google Scholar 

  53. Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72–7. https://doi.org/10.1097/INF.0b013e318233049d.

    Article  PubMed  Google Scholar 

  54. Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Chong WW, et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine. 2015;33(17):2015–21. https://doi.org/10.1016/j.vaccine.2015.03.012.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Varon E, Cohen R, Béchet S, Doit C, Levy C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine. 2015;33(46):6178–85. https://doi.org/10.1016/j.vaccine.2015.10.015.

    Article  PubMed  Google Scholar 

  56. Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M, et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine. 2016;34(38):4565–71. https://doi.org/10.1016/j.vaccine.2016.07.031.

    Article  PubMed  Google Scholar 

  57. • Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, et al. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine. 2017;35(32):4002–9. A study showing that invasive capacity differs among serotypes and likely by age. https://doi.org/10.1016/j.vaccine.2017.05.077.

    Article  CAS  PubMed  Google Scholar 

  58. •• Esposito S, Principi N. Strategies to develop vaccines of pediatric interest. Expert Rev Vaccines. 2017;16(2):175–86. A comprehensive review on vaccines in development. https://doi.org/10.1080/14760584.2017.1237875.

    Article  CAS  PubMed  Google Scholar 

  59. Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006–2015. Pediatr Infect Dis J. 2016;35(8):901–6. https://doi.org/10.1097/INF.0000000000001206.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kawaguchiya M, Urushibara N, Kobayashi N. Multidrug resistance in non-PCV13 serotypes of Streptococcus pneumoniae in northern Japan, 2014. Microb Drug Resist. 2017;23(2):206–14. https://doi.org/10.1089/mdr.2016.0054.

    Article  CAS  PubMed  Google Scholar 

  61. McElligott M, Vickers I, Meehan M, Cafferkey M, Cunney R, Humphreys H. Noninvasive pneumococcal clones associated with antimicrobial nonsusceptibility isolated from children in the era of conjugate vaccines. Antimicrob Agents Chemother. 2015;59(9):5761–7. https://doi.org/10.1128/AAC.00990-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, et al. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13. J Antimicrob Chemother. 2015;70(7):1960–4. https://doi.org/10.1093/jac/dkv061.

    CAS  PubMed  Google Scholar 

  63. Olarte L, Kaplan SL, Barson WJ, Romero JR, Lin PL, Tan TQ, et al. Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States. J Clin Microbiol. 2017;55(3):724–34. https://doi.org/10.1128/JCM.01778-16.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother. 2014;58(8):4923–7. https://doi.org/10.1128/AAC.02976-14.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN. Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagn Microbiol Infect Dis. 2014;80(1):19–25. https://doi.org/10.1016/j.diagmicrobio.2014.05.020.

    Article  CAS  PubMed  Google Scholar 

  66. Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, et al. Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts. Journal of the Pediatric Infectious Diseases Society. 2014;3(1):23–3287. https://doi.org/10.1093/jpids/pit057.

    Article  PubMed  Google Scholar 

  67. Metcalf BJ, Gertz RE Jr, Gladstone RA, Walker H, Sherwood LK, Jackson D, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22(1):60.e9–60. https://doi.org/10.1016/j.cmi.2015.08.027.

    Article  Google Scholar 

  68. Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29(3):525–52. https://doi.org/10.1128/CMR.00058-15.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One. 2013;8(10):e76309. https://doi.org/10.1371/journal.pone.0076309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MPE, Harrison TG, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32(34):4349–55. https://doi.org/10.1016/j.vaccine.2014.03.017.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emeritus Professor of Pediatrics, Università degli Studi di Milano, Milan, Italy

    Nicola Principi

  2. Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy

    Giuseppe Di Cara, Ilaria Bizzarri, Chiara Isidori, Paola Borgia, Costanza Mignini, Marco Saponara, Alberto Argentiero & Susanna Esposito

Authors
  1. Nicola Principi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Di Cara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilaria Bizzarri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Borgia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Costanza Mignini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Saponara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alberto Argentiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Susanna Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanna Esposito.

Ethics declarations

Conflict of Interest

No potential conflicts of interest relevant to this article were reported.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Respiratory Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Principi, N., Di Cara, G., Bizzarri, I. et al. Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use. Curr Infect Dis Rep 20, 1 (2018). https://doi.org/10.1007/s11908-018-0607-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-018-0607-z

Keywords

Search

Navigation